Posted by Michael Wonder on 25 Feb 2021
Allergan submits new drug application for investigational AGN-190584 for the treatment of presbyopia
25 February 2021 - If approved, this is expected to be the first eye drop to treat presbyopia.
Allergan today announced that it has submitted a new drug application to the U.S. FDA for investigational AGN-190584 (pilocarpine 1.25%) ophthalmic solution for the treatment of presbyopia.
The FDA is expected to act on the NDA by the end of 2021.
